Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Sunday's Featured News The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Author: Chris Markoch. Published: 1/18/2026. 
Summary - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. Investors typically look for companies with disruptive technologies, exposure to emerging trends, or compelling turnaround stories. Many of these companies will never survive or scale, but if just one succeeds, returns can be impressive. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks. This ranking is based on the number of MarketBeat subscribers following each company. While that's no guarantee of success, it can give an investor added conviction in a stock's potential. Jeff Clark has kept his Crossfire strategy close for years. But he's no longer working with his Silicon Valley clients… So, he can reveal the whole thing in a new free strategy session. It's a rare opportunity to learn his three-step process for potentially massive profits. Click here to watch now. Some investors define a penny stock as any share trading for $5 or less. This screener uses the traditional definition: stocks priced below $1. These issues are highly volatile, so conduct your own research and assess your risk tolerance before opening a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases, including influenza, norovirus and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bullish case for Vaxart centers on its innovative approach. If the company secures FDA approval and successfully scales production, its oral vaccines could reduce logistical barriers to mass immunization and open the door to significant licensing partnerships. Positive trial results or a commercial collaboration could materially change sentiment and valuation, given the stock's current low base. Clinical risk is the biggest challenge. Vaxart has yet to bring a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. The MarketBeat analyst ratings for Vaxart show only a single analyst covering the stock. That's not uncommon, but it should raise concerns for investors. VXRT also has just 18% institutional ownership. On a more positive note, the stock has about 2% short interest, which may temper some volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure and industrial sensing. The company's hardware and software solutions enable precise 3D mapping needed for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on developing compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bullish case for Microvision rests on two factors: the continued march toward vehicle automation and potential partnerships with major automotive manufacturers. If the company can demonstrate performance or cost advantages, it could secure supply agreements or licensing deals that significantly improve revenue visibility. Microvision's technology could also find applications beyond vehicles, including robotics and smart-city projects, adding optionality to its growth story. Despite the promise, Microvision faces stiff competition from LiDAR heavyweights like Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ) and Ouster (NYSE: OUST). The path to profitability is uncertain, and recurring delays in commercial adoption of LiDAR continue to frustrate investors. MVIS is covered by three analysts and has a consensus price target of $2.50 — roughly a 169% increase from its Jan. 15 closing price. Like many speculative names, Microvision has relatively low institutional ownership (around 30%) and high short interest (about 21%). That combination can lead to significant volatility that long-term investors should be prepared for. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates where artificial intelligence, data monetization and digital asset management intersect. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain and analytics tools, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems often overlook. The bullish thesis for Datavault AI lies in its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses — and potentially individuals — are seeking ways to safely monetize digital information. Datavault's technology could benefit from broader AI adoption and growing awareness of data sovereignty. Early-stage traction or strategic partnerships could catalyze investor confidence. Still, Datavault AI operates in a highly experimental space. The company's business model is evolving, and its path to meaningful revenue growth is unproven. Institutions own less than 1% of the stock, and short interest is over 16% as of this writing. Investors considering DVLT should view it as a long-term, speculative position based on belief in the data-as-an-asset thesis rather than near-term earnings potential.
| 
